A novel TLR7 agonist reverses NK cell anergy and cures RMA-S lymphoma-bearing mice

Toll-like receptor 7 (TLR7) agonists are potent immune stimulants able to overcome cancer-associated immune suppression. Due to dose-limiting systemic toxicities, only the topically applied TLR7 agonist (imiquimod) has been approved for therapy of skin tumors. There is a need for TLR7-activating com...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncoimmunology
Autors principals: Wiedemann, Gabriela Maria, Jacobi, Severin Johannes, Chaloupka, Michael, Krächan, Angelina, Hamm, Svetlana, Strobl, Stefan, Baumgartner, Roland, Rothenfusser, Simon, Duewell, Peter, Endres, Stefan, Kobold, Sebastian
Format: Artigo
Idioma:Inglês
Publicat: Taylor & Francis 2016
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5006928/
https://ncbi.nlm.nih.gov/pubmed/27622045
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2016.1189051
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars